1BHF image
Deposition Date 1998-06-08
Release Date 1998-10-21
Last Version Date 2024-11-13
Entry Detail
PDB ID:
1BHF
Title:
P56LCK SH2 DOMAIN INHIBITOR COMPLEX
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.80 Å
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 21 21 21
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:T-LYMPHOCYTE-SPECIFIC PROTEIN TYROSINE KINASE P56LCK
Gene (Uniprot):LCK
Chain IDs:A
Chain Length:108
Number of Molecules:1
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
1PA B PHE 4-(CARBOXYMETHYL)-L-PHENYLALANINE
Peptide-like Molecules
PRD_000406
Primary Citation
Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in SH2 domain binding.
J.Biol.Chem. 273 20238 20242 (1998)
PMID: 9685372 DOI: 10.1074/jbc.273.32.20238

Abstact

The crystal structure of human p56(lck) SH2 domain in complex with an inhibitor containing the singly charged p-(carboxymethyl)phenylalanine residue (cmF) as a phosphotyrosine (Tyr(P) or pY) replacement has been determined at 1.8 A resolution. The binding mode of the acetyl-cmF-Glu-Glu-Ile (cmFEEI) inhibitor is very similar to that of the pYEEI inhibitor, confirming that the cmFEEI inhibitor has a similar mechanism of SH2 domain inhibition despite its significantly reduced potency. Observed conformational differences in the side chain of the cmF residue can be interpreted in terms of maintaining similar interactions with the SH2 domain as the Tyr(P) residue. The crystal structure of the free p56(lck) SH2 domain has been determined at 1.9 A resolution and shows an open conformation for the BC loop and an open phosphotyrosine binding pocket, in contrast to earlier studies on the src SH2 domain that showed mostly closed conformation. The structural information presented here suggests that the carboxymethyl-phenylalanine residue may be a viable Tyr(P) replacement and represents an attractive starting point for the design and development of SH2 domain inhibitors with better pharmaceutical profiles.

Legend

Protein

Chemical

Disease

Primary Citation of related structures